GlassScriptPhysician profile
Norma Quijada
NPI 1134186877
$8,394.50
in general payments reported to CMS, 2019-2025
30 companies · $585 in 2025
The $585 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,283 · 2020: $1,961 · 2021: $1,072 · 2022: $832 · 2023: $777 · 2024: $885 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.86 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,612.29 | 2019-2025 | Sogroya, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $930.82 | 2019-2023 | |
| Mannkind Corporation | $729.03 | 2019-2024 | Afrezza |
| Lilly USA, LLC | $691.47 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $658.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $539.71 | 2019-2024 | Lokelma, Airsupra |
| Amneal Pharmaceuticals LLC | $457.12 | 2019-2025 | Unithroid |
| Insulet Corporation | $318.14 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $275.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.64 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $256.75 | 2019-2020 | |
| Exact Sciences Corporation | $212.81 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $188.24 | 2019-2025 | Capvaxive, Gardasil 9 |
| Dexcom, INC. | $179.89 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $159.27 | 2019-2025 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $120.09 | 2019 | |
| Shire North American Group INC | $119.57 | 2019 | |
| Endo Pharmaceuticals INC. | $113.90 | 2019 | |
| Amgen INC. | $101.75 | 2022-2025 | Tepezza, Repatha |
| Ultragenyx Pharmaceutical INC. | $74.33 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.52 | 2022-2024 | |
| Ibsa Pharma INC. | $47.17 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $46.24 | 2024-2025 | |
| Horizon Therapeutics Plc | $45.39 | 2019-2022 | |
| Pfizer INC. | $44.33 | 2019-2022 | |
| Medtronic, INC. | $39.45 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $30.13 | 2025 | |
| Senseonics, Incorporated | $29.00 | 2019 | |
| Esperion Therapeutics, INC. | $25.82 | 2020-2024 | Nexletol |
| Hologic Sales and Service, LLC | $24.16 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Quijada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.